MetaCap

Creative Medical Technology (CELZ) vs Scilex (SCLX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Scilex is the larger company by market cap ($4.0 million vs $3.1 million), about 1.3 times the size, while Creative Medical Technology is growing revenue faster (-45.5% vs -46.5%). Scilex converts more of its revenue into profit, with a net margin of -1236.4% versus -99916.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CELZ-54.72%SCLX-83.79%
+4%-42%-88%
Oct 7, 20261 yearNov 20, 2026
CELZ-52.00%SCLX-80.62%
+4%-40%-85%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CELZ versus SCLX key metrics
MetricCELZSCLX
Share price$0.4025$0.5658
Market cap$3.06M$3.98M
1-day change-8.52%-12.95%
YTD return—-92.55%
1-year return—-95.96%
5-year return—-99.74%
Forward P/E—0.78
EPS (TTM)$-1.99$-49.70
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.00K$30.25M
Revenue growth (YoY)-45.45%-46.54%
Net income (latest FY)$-6.00M$-374.05M
Gross margin63.43%415.83%
Operating margin-102380.23%-1143.71%
Net margin-99916.80%-1236.42%
52-week high$4.72$14.34
52-week low$0.40$0.50
Distance from 52-week high-91.47%-96.05%
Analyst consensusnone—
Avg. price target upside+4868.94%—
Average volume478.25K56.11K
Shares outstanding7.60M7.03M
Employees434
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Scilex is more profitable, keeping -1236.4 cents of every revenue dollar as net income versus -99916.8 cents for Creative Medical Technology.

About Creative Medical Technology

CELZ stock →

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4 employees

About Scilex

SCLX stock →

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees

CELZ vs SCLX FAQ

Which is bigger, Creative Medical Technology or Scilex?

Scilex (SCLX) is larger, with a market capitalization of $3.98M compared with $3.06M for Creative Medical Technology (CELZ).

Are Creative Medical Technology and Scilex in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons